KRATOS ENERGY & INFRASTRUCTURE LTD.

Lords Mark Industries Ltd has provided an update on a High Court of Delhi order dated June 1, 2026, concerning a petition filed by Bennett Coleman and Co. Ltd. (BCCL) under Section 9 of the Arbitration and Conciliation Act, 1996. BCCL sought interim reliefs related to the conversion of warrants subscribed by them and the proposed listing of the company's shares. Lords Mark Industries informed the court that it will issue 10,28,483 equity shares to BCCL at a conversion price of ₹158 per share as per their agreement. Crucially, no adverse order was passed against the company. The filing aims to inform shareholders and the stock exchange about the proceedings and the company's compliance.

Lords Mark Industries Limited announced the appointment of four individuals as Additional Directors in the category of Independent Non-Executive Directors. The appointments, effective June 4, 2026, are subject to shareholder approval at the upcoming Annual General Meeting. The appointees have met all regulatory requirements, including declarations of independence and non-disqualification. Each director is appointed for a term of five consecutive years, from June 4, 2026, to June 3, 2031, and will not be liable to retire by rotation. The board meeting where these appointments were approved commenced at 11:30 AM and concluded at 3:40 PM on June 4, 2026.

Lords Mark Industries Ltd. approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, during its board meeting held on May 29-30, 2026. The board did not recommend any dividend for the financial year ended March 31, 2026. Standalone total assets stand at ₹1,30,588.44 Lacs. Profit for the period is ₹5,276.08 Lacs.

The Board Meeting of Lords Mark Industries Ltd, initially held on May 29, 2026, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026, and recommendation of final dividend, will continue on May 30, 2026. The trading window will remain closed until 48 hours after the declaration of the audited financial results. The outcome of the meeting will be submitted to the Stock Exchange as per SEBI regulations.

Lords Mark Industries Ltd has scheduled a Board Meeting on May 29, 2026, to consider and approve the standalone and consolidated audited financial results for the fourth quarter and financial year ended March 31, 2026. The board will also consider recommending a final dividend, if any, for the financial year ending March 31, 2026. The trading window for the company's shares is closed from April 1, 2026, until 48 hours after the declaration of the audited financial results.

Lords Mark Industries Ltd has launched the world’s first cost-optimised AI-powered hemodialysis centre at Shakti Hospital, Ahmedabad. The centre utilizes the indigenously developed Lord’s Renal Renalyx Machine, integrating AI, IoT, and cloud connectivity for real-time monitoring and predictive clinical insights. The company plans to establish 50 dialysis centers by March 2027 and is pursuing US FDA approval for global expansion. The Renalyx Machine aims to reduce dependency on imported machines and lower costs, positioning India as a leader in AI-based medical devices.

The 6th Monitoring Committee meeting of Lords Mark Industries Ltd (formerly Kratos Energy & Infrastructure Limited) on April 28, 2026, approved several key actions. The Bombay Stock Exchange (BSE) has expressed satisfaction with submitted documents, and listing and trading are tentatively scheduled for June 5, 2026. The Committee unanimously approved the handover of management and control to the reconstituted Board of Directors, coinciding with the trading commencement. It also approved the allotment of 42,65,96,580 equity shares of ₹10/- each to eligible shareholders as of November 5, 2025, based on a 1.25:1 swap ratio. The reconstituted Board has the liberty to appoint Independent Directors by June 5, 2026. The erstwhile Resolution Professional will coordinate with BSE to ensure all regulatory requirements for listing are reviewed and trading resumption is approved before the end of May 2026. Conversion of all pending warrants of the erstwhile company into equity shares of Lords Mark Industries Limited will occur immediately following listing and commencement of trading. Professional fees and expenses of the Erstwhile RP totaling ₹9,44,000/- were ratified.

Lords Mark Industries Ltd has been granted a license by the Central Licensing Authority under the Medical Devices Rules, 2017, to manufacture a high-risk medical device for sale or distribution. The license is specifically for the "LordsMed HIV 1&2 Self Test" for export purposes, targeting markets in Africa, Latin America, and Europe. This approval makes Lords Mark among the second company in India and one of nine globally to receive such a license for this Class D In-vitro Diagnostic Device. The license, MFG/IVD/2023/000058 (Endorsement No. 8), was granted/endorsed on January 14, 2026. This strategic regulatory approval significantly strengthens the company's presence in the global healthcare and diagnostics segment by enabling the manufacture and export of a critical self-testing device.

Lords Mark Industries Ltd has announced the closure of the trading window for the fourth quarter ending on 31.03.2026. The trading window will remain closed till 48 hours after the declaration of Audited Financial results for the quarter/ year ending March 31, 2026 becomes generally public information. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended by the Regulations, 2018, and the policy framed and approved by the Board. All concerned are advised not to deal in any manner in the securities of the Company during the closure period of the Trading Window.

Lords Mark Industries Ltd has entered into a Technology Transfer Agreement (TTA) with the Centre for Materials for Electronic Technology (C-MET) for the manufacturing and commercialization of an AI-powered, radiation-free wearable device for early detection of breast cancer. The device, which utilizes high-precision thermal sensors and AI-driven temperature mapping, is non-invasive, painless, and eliminates radiation exposure. The global breast cancer diagnostics market is projected to reach approximately USD 12.88 billion by 2035, and this partnership positions the Company at the forefront of the indigenous Med-Tech sector. The product is expected to be available for commercial use globally by the end of the current calendar year.